The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer-Reference-Cited by-同舟云学术

The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer

Published:2010-09-13 Issue:10 Volume:19 Page:1235-1243
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Isaacs John T

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/13543784.2010.514262

Reference49 articles.

1. Cancer Statistics, 2009

2. A history of prostate cancer treatment

3. American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Nonhormonal Therapy for Men With Metastatic Hormone-Refractory (castration-resistant) Prostate Cancer

4. A novel quinolinecarboxamide with interesting immunomodulatory activity

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel effect of topical Roquinimex and its combination with Clobetasol on an imiquimod-induced model of psoriasis in mice;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-01-24

2. Resistance to taxane chemotherapies in prostate cancer;Therapy Resistance in Prostate Cancer;2024

3. Repurposing of antiangiogenic agents for treatment of vascular anomalies;Pharmacology & Therapeutics;2023-10

4. Third generation quinoline‐3‐carboxamide transcriptional disrupter of HDAC4, HIF‐1α, and MEF‐2 signaling for metastatic castration‐resistant prostate cancer;The Prostate;2023-08-09

5. Design, Synthesis, and Biological Examination of N‐ Phenyl‐6‐fluoro‐4‐hydroxy‐2‐quinolone‐3‐carboxamides as Anticancer Agents;ChemistrySelect;2022-05-17